Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire

Tarhini A1,2, Lin Y3, Lin H3, Rahman Z3, Vallabhaneni P3, Mendiratta P4, Pingpank JF3, Holtzman MP3, Yusko EC5, Rytlewski JA5, Rao UNM3, Ferris RL3, Kirkwood JM3 1 UPMC Hillman Cancer Center, Pittsburgh, USA. tarhina1@ccf.org. 2 Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, 9500 Euclid Ave CA6-157, Cleveland, OH, 44195, USA. tarhina1@ccf.org. 3 UPMC Hillman Cancer Center, Pittsburgh, USA. 4 Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, 9500 Euclid Ave CA6-157, Cleveland, OH, 44195, USA. 5 Adaptive Biotechnologies, Seattle, USA.